Investigation Report on China's Doxofylline Market 2010-2019 - Market Expected to Expand

Aug 06, 2015, 07:10 ET from Research and Markets

DUBLIN, Aug. 06, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/wf6ff4/investigation) has announced the addition of the "Investigation Report on China's Doxofylline Market, 2010-2019" report to their offering.

With the climatic and environmental changes, seasonal asthma has become the main reason for respiratory ailments. According to an epidemiological survey, the incidence of respiratory ailments is 16% of the incidence of all diseases. About 280 million people in the world suffer from different degrees of seasonal asthma. The situation is more serious in industrialized countries and regions where tobacco consumption is high with 5% of adults and 20% of children there having been attacked by this disease. Nearly 300 million people in China contract respiratory ailments, among which over 50 million suffer from cough with an annual growth rate of 4% and 15-20 million asthma.

Doxofylline, a derivative of theophylline, is a methylxanthine anti-bronchospasm drug for the treatment of bronchial asthma, panting chronic bronchitis and breathing difficulties caused by other bronchospasm. It is also a common drug for acute and chronic obstructive airway disorders. Unlike other methylxanthines, dexofylline has no side effects on gastrointestinal tract, nervous system, heart and kidney. First developed and marketed by ITALY and ABC company in 1988, doxofylline has now become the best-selling drug in many countries like the US, Japan, Ireland and Canada. Chinese enterprises begun manufacturing improvements in 1992 and has now developed such dosage forms as syrup, tablet, injection and APIs. Compared with traditional theophylline and aminophylline, doxofylline has better efficacy and less toxicity and therefore is worthwhile for spreading in clinical practice.

Doxofylline develops fast after entering China, annual sales value rising from CNY 124 million in 2010 to CNY 224 million in 2014 and CAGR reaching up to 15.9% during the period of 2010-2014. Doxofylline enjoys a vast demand in China. Currently, Fuhe Huaxing Pharmaceutical Shares Co., Ltd, Xi'an Bosen BioPharma Co., Ltd, Zhejiang Hansheng Pharmaceutical Co., Ltd of Beisheng Pharma, Kaifeng Canon Pharmaceutical Co., Ltd and ReYoung Pharmaceutical Co., Ltd all take up certain shares in the market, among which Fuhe Huaxing Pharmaceutical Shares Co., Ltd has the largest market share of 27.8% with sales value in 2014 reaching up to CNY 62.33 million.

As environmental pollution worsens in China, the incidence of respiratory ailments will keep growing. Therefore, the market size of doxofylline in China is expected to keep expand in the next few years.

Key Topics Covered:

1 Related Concepts of Doxofylline

2 Market Profile of Doxofylline in China

3 Survey on Sales Status of Doxofylline in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Doxofylline in China, 2010-2014

5 Survey on Dosage Forms of Doxofylline in China, 2010-2014

6 Reference Price of Doxofylline in Chinese Hospitals in 2014

7 Major Manufacturers of Doxofylline in Chinese Market, 2010-2014

8 Market Outlook of Doxofylline in China, 2015-2019

Companies Mentioned

- Fuhe Huaxing Pharmaceutical Shares Co., Ltd
- Xi'an Bosen BioPharma Co., Ltd
- Zhejiang Hansheng Pharmaceutical Co., Ltd of Beisheng Pharma
- Kaifeng Canon Pharmaceutical Co., Ltd
- ReYoung Pharmaceutical Co., Ltd

For more information visit http://www.researchandmarkets.com/research/wf6ff4/investigation

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com